Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori:

Alessandra Raimondi,Pierangela Sepe,Melanie Claps,Marco Maccauro,Gianluca Aliberti,Filippo Pagani,Giulia Apollonio,Giovanni Randon,Giorgia Peverelli,Ettore Seregni,Elena Verzoni,Giuseppe Procopio

Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori:

2020

Alessandra Raimondi
Pierangela Sepe
Melanie Claps
Marco Maccauro
Gianluca Aliberti
Filippo Pagani
Giulia Apollonio
Giovanni Randon
Giorgia Peverelli
Ettore Seregni
Elena Verzoni
Giuseppe Procopio

Introduction:Therapeutic decision-making in metastatic castration-resistant prostate cancer (mCRPC) represents an open challenge. Radium-223 is approved for patients with symptomatic bone metastase...

Keywords:

Prostate cancer
Pathology
Castration
Oncology
Internal medicine
Castration Resistance
Radium-223
Medicine
castration resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations